Corbus Pharmaceuticals (CRBP)

• Market cap: $164M
• 1 day: -1.56%
• 5 days: -2%
• 1 month: 6.38%
• 3 months: -15.65%
• 6 months: -0.23%
• Year to date: 12.33%
• 1 year: 1.61%
• 5 years: -79.82%
• 10 years: -89.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 36